Earnings call transcript: Krsnaa Diagnostics posts record Q2 2026 revenue, shares fall

Krsnaa Diagnostics reported record Q2 FY27 revenue of INR 271 crore, up 32% year over year, while profit after tax rose only 3% to INR 25 crore; EBITDA margin narrowed 200bps to 27%. H1 revenue reached INR 507 crore, up 27%, but H1 PAT fell 9% to INR 41 crore, with higher project ramp-up costs, depreciation and finance costs weighing on profitability. Receivables stood at INR 470 crore, and management expects about INR 200 crore in collections in Q3; it targets cash-based revenue of 40%–45% of the mix by FY27-end and expects retail to reach absolute break-even by late Q3 or early Q4. Shares fell 3.72% to $480.15, near the reported 52-week low of $463.10.

Analysis

The key issue is not whether the new network can generate volume, but whether incremental volume converts into cash and earnings. A shift toward lower-priced PPP work can lift test counts while diluting revenue per test; therefore, volume growth alone is a weak operating-leverage signal. The increase in payables alongside elevated receivables also raises a second-order risk: suppliers may be funding expansion while government collections lag, potentially masking the cash cost of growth. Management’s expected collections and margin recovery are catalysts, not yet verified outcomes. Cash-based projects could reduce financing drag, but they do not automatically improve project-level margins, and the promoter warrants offer only partial committed capital while conversion may dilute shareholders.

Near term (days to weeks), the weak price trend may persist as investors wait for evidence on collections. Over 1–3 months, Q3 receipts and the retail break-even milestone are the tests; over 6–18 months, Rajasthan utilization and a larger cash-based mix determine whether scale produces better returns. Contrarian point: the market may be discounting the ramp-up too heavily if most setup costs are already recognized, but the receivables/payables profile makes a low share price insufficient evidence of value. Falsify the cautious view with documented collections, improving working-capital days, and sustained EBITDA-margin recovery; worsening overdue receivables or further margin erosion would strengthen it.

Key Decisions for Investors

• Keep Krsnaa Diagnostics underweight / avoid adding ahead of cash-flow proof; reassess after Q3 results rather than trading the revenue-growth headline.
• Set an event alert for the stated Q3 collections: verify cash received in filings or reported cash-flow data, not management visibility alone. A material shortfall, or receivables remaining elevated as payables normalize, is a bearish trigger.
• Consider a relative-value hedge only after checking valuation and business-mix comparability: long a diversified diagnostics peer such as Dr Lal PathLabs or Metropolis Healthcare against Krsnaa Diagnostics. Do not assume the peers have superior economics without confirming current growth, margins, and valuation.
• Upgrade the thesis only if cash-based revenue share rises alongside lower working-capital days and EBITDA margins improve; rising test volumes without those conversions would not validate operating leverage.